- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: clone OGD1.0.0  | PF-06252616 | PF06252616
Compound class: Antibody
Comment: Domagrozumab is a humanized monoclonal antibody targeting myostatin (MSTN), being investigated for potential therapeutic action in muscle wasting diseases.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with sequences claimed in patent US8992913 .
1. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. (2002)
Functional improvement of dystrophic muscle by myostatin blockade.
Nature, 420 (6914): 418-21. [PMID:12459784]
2. Mader MM, Apgar JR, Parris KD. (2015)
Antagonist antibodies against GDF-8 and uses therefor.
Patent number: US8992913 B2. Assignee: Pfizer Inc.. Priority date: 15/06/2012. Publication date: 31/03/2015.